Acelrx pharmaceuticals reports first quarter 2023 financial results and provides corporate update

Request for emergency use authorization of niyad™ submitted to the fda in april divestment of dsuvia® to alora pharmaceuticals closed april 3, 2023 $13.4 million in cash as of march 31, 2023 webcast and conference call to be held today at 4:30 p.m. edt hayward, calif.
ACRX Ratings Summary
ACRX Quant Ranking